Patient-reported Data on the Severity of Von Willebrand Disease

Overview

Journal Haemophilia

Specialty Hematology

Date 2024 Oct 15

PMID 39403864

Authors

Calvin B van Kwawegen

Karin Fijnvandraat

Marieke J H A Kruip

Joke de Meris

Saskia E M Schols

Karina Meijer

Johanna G van der Bom

Marjon H Cnossen

Karin P M van Galen

Ferdows Atiq

Jeroen Eikenboom

Frank W G Leebeek

Affiliations

Soon will be listed here.

Abstract

Introduction: The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.

Aim: The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.

Materials And Methods: Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).

Results: We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity.

Conclusion: This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.

Citing Articles

Patient-reported data on the severity of Von Willebrand disease.

van Kwawegen C, Fijnvandraat K, Kruip M, de Meris J, Schols S, Meijer K Haemophilia. 2024; 30(6):1348-1356.

PMID: 39403864 PMC: 11659499. DOI: 10.1111/hae.15103.

References

Castaman G, Tosetto A, Rodeghiero F . Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. J Thromb Haemost. 2009; 7 Suppl 1:71-4. DOI: 10.1111/j.1538-7836.2009.03381.x. View

Sadler J, Budde U, Eikenboom J, Favaloro E, Hill F, Holmberg L . Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4(10):2103-14. DOI: 10.1111/j.1538-7836.2006.02146.x. View

McHorney C, Ware Jr J, Raczek A . The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31(3):247-63. DOI: 10.1097/00005650-199303000-00006. View

Teela L, Luijten M, Kuijlaars I, van Gastel T, van Hoorn E, Gouw S . Psychometrics of the patient-reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banks. Res Pract Thromb Haemost. 2023; 7(6):102159. PMC: 10518485. DOI: 10.1016/j.rpth.2023.102159. View

van Balen E, Haverman L, Hassan S, Taal E, Smit C, Driessens M . Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands. J Thromb Haemost. 2021; 19(11):2687-2701. PMC: 8596807. DOI: 10.1111/jth.15454. View

Atiq F, Mauser-Bunschoten E, Eikenboom J, van Galen K, Meijer K, de Meris J . Sports participation and physical activity in patients with von Willebrand disease. Haemophilia. 2018; 25(1):101-108. PMC: 7379650. DOI: 10.1111/hae.13629. View

Cuevas-Trisan R . Balance Problems and Fall Risks in the Elderly. Clin Geriatr Med. 2019; 35(2):173-183. DOI: 10.1016/j.cger.2019.01.008. View

Punt M, Blaauwgeers M, Timmer M, Welsing P, Schutgens R, van Galen K . Reliability and Feasibility of the Self-Administered ISTH-Bleeding Assessment Tool. TH Open. 2019; 3(4):e350-e355. PMC: 6884422. DOI: 10.1055/s-0039-3400483. View

Kempers E, van Kwawegen C, de Meris J, Schols S, van Galen K, Meijer K . Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia. 2021; 28(2):278-285. PMC: 9304182. DOI: 10.1111/hae.14475. View

10.

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View

11.

de Wee E, Knol H, Mauser-Bunschoten E, van der Bom J, Eikenboom J, Fijnvandraat K . Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost. 2011; 106(5):885-92. DOI: 10.1160/TH11-03-0180. View

12.

Hays R, Morales L . The RAND-36 measure of health-related quality of life. Ann Med. 2001; 33(5):350-7. DOI: 10.3109/07853890109002089. View

13.

Leebeek F, Atiq F . How I manage severe von Willebrand disease. Br J Haematol. 2019; 187(4):418-430. PMC: 6899759. DOI: 10.1111/bjh.16186. View

14.

de Wee E, Fijnvandraat K, De Goede-Bolder A, Mauser-Bunschoten E, Eikenboom J, Brons P . Impact of von Willebrand disease on health-related quality of life in a pediatric population. J Thromb Haemost. 2010; 9(3):502-9. DOI: 10.1111/j.1538-7836.2010.04175.x. View

15.

McHorney C, Ware Jr J, Lu J, Sherbourne C . The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32(1):40-66. DOI: 10.1097/00005650-199401000-00004. View

16.

Pofahl W, Pories W . Current status and future directions of geriatric general surgery. J Am Geriatr Soc. 2003; 51(7 Suppl):S351-4. DOI: 10.1046/j.1365-2389.2003.51347.x. View

17.

Federici A . Clinical diagnosis of von Willebrand disease. Haemophilia. 2004; 10 Suppl 4:169-76. DOI: 10.1111/j.1365-2516.2004.00991.x. View

18.

Jenkins P, Earle-Richardson G, Slingerland D, May J . Time dependent memory decay. Am J Ind Med. 2002; 41(2):98-101. DOI: 10.1002/ajim.10035. View

19.

Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones K, OSullivan J . Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017; 130(21):2344-2353. PMC: 5881608. DOI: 10.1182/blood-2017-05-786699. View

20.

Nichols W, Hultin M, James A, Manco-Johnson M, Montgomery R, Ortel T . von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008; 14(2):171-232. DOI: 10.1111/j.1365-2516.2007.01643.x. View